Unicycive Therapeutics reported third quarter 2026 financial results and provided a business update regarding its New Drug Application (NDA) for oxylanthanum carbonate (OLC). The FDA has accepted the NDA resubmission with a PDUFA target action date of March 25, 2027, following a previous Complete Response Letter related to manufacturing vendor deficiencies.
“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients. With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”
Unicycive Therapeutics reported a net loss of $7.0 million for the quarter ended September 30, 2026, compared to $6.0 million in the prior year period. The company's cash position strengthened to $42.0 million, supported by $39.0 million in net proceeds from financing activities during the first nine months of 2026.
Unicycive Therapeutics appointed Meredith S. Manning as an independent director to its board, effective October 1, 2026. Ms. Manning, who previously served as Chief Commercial Officer of Soleno Therapeutics, will also serve as Chairperson of the Nominating and Corporate Governance Committee. The company also announced the resubmission of its New Drug Application for Oxylanthanum Carbonate with a new manufacturing vendor.
A securities class action lawsuit has been filed against Unicycive Therapeutics and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges violations of federal securities laws regarding public statements about the company's New Drug Application for oxylanthanum carbonate. Unicycive stated it believes the claims are meritless and intends to vigorously defend the action.